Nilotinib - Novartis Pharmaceuticals Corporation
Alternative Names: AMN-107; Nilotinib-nanoparticle-formulation-Xspray-Pharma; RightSize-nilotinib; TasignaLatest Information Update: 30 Jan 2024
At a glance
- Originator Novartis Pharmaceuticals Corporation
- Developer Centre Hospitalier Univeristaire De Lille; Dana-Farber Cancer Institute; Hospital for Special Surgery; Novartis Pharmaceuticals Corporation; Seoul St. Mary's Hospital; University Health Network of Toronto; University of California, San Diego
- Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Imidazoles; Ketones; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia
- Phase II Acral lentiginous melanoma; Gastrointestinal stromal tumours; Glioblastoma; Graft-versus-host disease; Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I/II Acute myeloid leukaemia
- No development reported Colorectal cancer; Head and neck cancer; Hypereosinophilic syndrome; Systemic scleroderma
- Discontinued Eosinophilia
Most Recent Events
- 09 Dec 2023 Efficacy and adverse event data from a phase II DANTE trial in Chronic myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 02 Oct 2023 Novartis completes a phase II trial for Gastrointestinal stromal tumours in Japan (PO) (NCT01863745)
- 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in Hypereosinophilic-syndrome in Unknown (PO)